Blog Category

Press Releases

First US Patient Enrolled in COVA, a Multinational Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

,

/

13 October 2020

Biophytis Trading will resume on September 30, 2020 at 3.00pm CEST

,

/

30 September 2020

Biophytis announces a € 10 million capital increase through private placement

,

/

30 September 2020

Biophytis shares and BSA trading is suspended pending a new press release

,

/

30 September 2020

Biophytis Reports H1 2020 Financial Results and Provides Business Update

,

/

18 September 2020

Biophytis announces the issuance of a €3 million tranche of ORNANE

,

/

14 September 2020

SEPTEMBER 8, 2020

,

/

8 September 2020

SEPTEMBER 1ST, 2020

,

/

31 August 2020

Biophytis provides an update on SARA-INT, a Phase 2b clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia

,

/

28 August 2020

Biophytis Receives Approval from Brazilian Health Regulatory Agency to Start COVA, a Phase 2/3 Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID19 Related Respiratory Failure

,

/

4 August 2020

Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

,

/

27 July 2020

Biophytis announces a € 6.1 million capital increase through private placement

,

/

3 July 2020